Sinusitis Treatment Market to Reach USD 4.52 Billion by 2033 as Rising Chronic Sinusitis Prevalence, Biologic Therapy Adoption, and Minimally Invasive Surgical Innovation Drive Steady Global Growth
The increasing global prevalence of chronic rhinosinusitis, nasal polyposis, and allergic sinusitis — driven by rising air pollution levels, expanding allergen exposure, and growing rates of respiratory comorbidities — is generating sustained and broad-based demand for both pharmacological and surgical sinusitis treatment options. The recent clinical emergence of biologic therapies targeting Type 2 inflammation pathways in severe chronic rhinosinusitis with nasal polyps is opening a high-value new treatment category that is meaningfully expanding the sinusitis treatment market's revenue potential beyond conventional corticosteroids and antibiotics. As minimally invasive endoscopic surgical techniques become more widely adopted, drug-eluting sinus stent technology advances, and biologic treatment protocols establish themselves in specialist ENT practice, the sinusitis treatment market is entering a period of clinically and commercially compelling evolution through 2033. HOUSTON, Tex...